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Background Certain types of human papillomavirus (HPV) are associated with cervical intraepithelial
neoplasia (CIN) and invasive cervical carcinoma. The study addressed the expression and detection of
HPV genotypes in cervical and vaginal specimens of women with normal and abnormal cytology by
polymerase chain reaction (PCR), each woman serving as her own control.
Methods Study participants (127) were subgrouped into CIN-positive and CIN-negative, based on cytology
screening, and endocervical and vaginal scrapes were collected by a gynecologist and placed immediately in
saline. HPV DNA was assessed by PCR, and HPV genotypes were determined by hybridization of
PCR products with type-specific biotinylated probes.
Results Of the 127 participants, 55 tested positive and 72 tested negative for HPV DNA. While there
was no difference between the two groups with regards to age or to number of pregnancies, higher numbers
of smokers and of women with multiple sexual partners and abnormal cytology were seen in the
HPV-positive group (P< 0.001). HPV DNA was detected in the vaginal scrapes of all HPV-positive, but in
none of the HPV-negative women (sensitivity and specificity¼ 1.0). Furthermore, the HPV genotype
was the same in vaginal and endocervical specimens in all the HPV-positive women.
Conclusion HPV detection by PCR, using endocervical or vaginal sampling, is a sensitive and highly specific
test for the identification of HPV infection, in particular in women with cytomorphologically normal
cervices.
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INTRODUCTION
Infection with human papillomavirus (HPV) is now recognized
as a major causative agent of cervical intraepithelial neoplasia
(CIN) [1,2]. More than 80 types of HPV have been character-
ized [3]. Early detection of CIN may result in the prevention of
most cases of cervical cancer [4,5]. Traditional screening for
HPV infection relied on the Papanicolaou smear. However, in
view of the high number of false negatives and positives
associated with it, coupled with the need for more sensitive
methods of detection, especially in women with a high suspi-
cion of HPV infection, cytology screening is no longer suffi-
cient to assess cervical neoplasia [6,7]. In contrast, identification
of HPV DNA by a molecular technique was more sensitive
in identifying and monitoring the progression of CIN
[7,8].
In so far as infection with HPV is the strongest risk factor for
cervical neoplasia, several methods have been proposed to
monitor HPV infection, including the polymerase chain reac-
tion (PCR) [6,7,9]. This involved a gynecologist extracting
HPV DNA from endocervical epithelial cells using a speculum
[10], a cytobrush, or similar devices [11]. As proper assessment
of HPV infection depends on the quality of specimen collected
and of technique used in detecting HPV, and as speculum-
assisted endocervical sampling was frequently associated with
drawbacks, notably with patient compliance and its level of
invasiveness, amongst others [11], alternative sampling meth-
ods, including vaginal sampling, were investigated to yield
sufficient cells without significantly inconveniencing the patient
[11,12]. Concordance rates varied between speculum-assisted
endocervical sampling and other collection methods, including
cytobrush, self-administered tampons and swabs [1,11,12],
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which highlighted the need for refinement in specimen
collection, and hence manipulation [10].
The objective of this study was to assess the utility and
sensitivity of vaginal testing in detecting HPV genotypes in
women with normal and abnormal cytology, and to evaluate the
feasibility of using vaginal testing in the routine diagnosis of
HPV infection. In addition, the presence of specific HPV
genotypes in endocervical and vaginal scrapes was also assessed.
SUBJECTS AND METHODS
Study subjects
The study comprised 127 women, of whom 55 were followed
because of confirmed endocervical HPV infection, and 72 were
free of HPV, as assessed by a pathologist from immunohisto-
chemistry and confirmed by PCR. For the purpose of this
study, both endocervical and vaginal specimens were collected
at the same time to minimize variation in viral load, and hence
sensitivity, between visits. All participants were asked to com-
plete a self-administered confidential questionnaire, which
included questions about age, marital status, smoking, preg-
nancies, sexual behavior (number of male partners), concurrent
infections and results of Papanicolaou smear (and date taken).
After the purpose and implications of the findings had been
explained to all participants, and after all the ethical require-
ments of the institute had been met, the participants were asked
to sign an informed consent form.
Specimen collection
Endocervical scrapes were collected from study participants by a
gynecologist using a speculum-assisted modified Ayre spatula
(Figure 1), placed in balanced saline solution, and transported
on ice to the laboratory. Vaginal scrapes were collected, also by a
gynecologist, by introducing an Ayre spatula into the vagina,
after separating the labia minora to visualize the introitus, and
rotating the spatula intravaginally through 1808 to collect
scrapings, which were immediately placed in balanced saline
solution. Total genomic DNA was extracted from both endo-
cervical and vaginal scrapes by the phenol–chloroform method,
as is standard, and was dissolved in nuclease-free water.
HPVDNA amplification
DNA samples were amplified with the L1 consensus HPV
primers MY09/MY11 [13]. In parallel, amplification of the
constitutively expressed gene, b-actin, was performed on every
sample in order to control for DNA integrity and PCR
amplification. PCR conditions comprised an initial denatura-
tion for 2.5 min at 98 8C, 41 cycles of denaturation for 30 s at
92 8C, annealing for 30 s at 56 8C, and extension for 45 s at
72 8C. PCR products were electrophoresed on ethidium bro-
mide-stained Agarose-1000 (Life Technologies, Paisley, UK) gel
(2%), and visualized under ultraviolet trans-illumination. HPV
genotypes were determined by hybridization with genotype-
specific biotinylated DNA probes, and visualized by DNA
enzyme immunoassay (DEIA) following the manufacturer’s
specification (DiSorin, Salluggia, Italy). The nucleotide
sequence of the consensus primers for HPV (MY09, MY11)
and b-actin genes, and for the biotinylated HPV primers are
shown in Table 1.
Figure1 Ayre’s spatula; after collectionof cervico-vaginal scrapes, the sam-
ple collection end is dipped into balanced saline and transported to the la-
boratory for processing.
Table1 Oligonucleotide primer sequence for HPVgenotpyes
Oligonucleotide Primer ID Sequence (5030 orientation)
Consensus primers
HPV; forward MY09 CGTCC(A,C) A(A,G)(A,G) GGA (A,T)AC TGATC
HPV; reverse MY11 GC(A,C) CAGGG(A,T) CATAA(C,T) AATGG
b-Actin; forward BA-1 GTGGGGCGCCCCAGGCACCA
b-Actin; reverse BA-2 CTCCTTAATGTC ACGCACGAT TTC
HPV probes (biotinylated)
HPV6 MY12 CATCCGTAACTACATCTTCCA
HPV11 MY13 TCTGTGTCTAAATCTGCTACA
HPV16 MY14 CATACACCTCCAGCACCTAA
HPV18 WD74 GGATGC TGCACCGGC TGA
HPV33 MY16 CACACA AGTAAC TAGTGACAG
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Statistical analysis
Statistical analysis was performed on SPSS statistics software. Data
were expressed as percentages of the mean or as genotype
frequency. Student’s t-test and Pearson w2-test were used to
assess intergroup significance.
RESULTS
Patient profile
Of the 127 women who participated in the study, 55 were
positive and 72 were negative for HPV DNA as determined by
PCR, using endocervial HPV detection as the standard. The
characteristics of the study participants as obtained from their
questionnaire and pathology reports are listed in Table 2. While
HPV-positive and HPV-negative women were similar in age
(33.0 7.3 and 33.9 6.9 years, respectively, P¼ 0.52), and
pregnancies (40/55 and 46/72, respectively, P¼ 0.57), a higher
prevalence of smokers (31/55 vs. 21/72, P< 0.001), multiple
male sexual partners (31/55 vs. 27/72, P< 0.001), and abnor-
mal cytology (48/55 vs. 15/72, P< 0.001) was seen in HPV-
positive vs. HPV-negative women, respectively (Table 2). In
addition, seven of the 55 HPV-positive women (12.73%) had
normal Papanicolaou smears, while 15 of the HPV-negative
women (20.83%) had mild dysplasia (CIN grade I). All CIN
Table 2 Profile of study group
Total HPV þve HPV^ve P value
n 127 55 72
Age (years)
meanSD 33.66.9 33.07.3 33.96.9 0.52a
range 21^56 21^48 21^56
Smoker 52/127 (40.9)b 31/55 (56.4)b 21/72 (29.2)b <0.001c
Pregnancies 86/127 (67.7)b 40/55 (72.7)b 46/72 (63.9)b 0.57c
Multiple partnersd 58/127 (45.7)b 31/55 (56.4)b 27/72 (37.5)b <0.001c
Papanicolaou smear 63/127 (49.6)b 48/55 (87.3)b 15/72 (20.8)b <0.001c
CINgrade
0 64 (50.39%)b 7 (10.94%)b 57 (80.06%)b <0.001c
I 43 (33.86%)b 28 (65.12%)b 15 (34.88%)b
II 8 (6.30%)b 8 (100%)b 0 (0.0%)b
III 12 (9.45%)b 12 (100%)b 0 (0.0%)b
aStudent’s t-test (two-tailed).
bPercentage of total within group.
cPearson’s w2-test.
dDefined as having more than one male sexual partner.
Table 3 HPVgenotypes in vaginal and cervical scrapes
HPVgenotype Number Percentagea CIN þve Percentage Cervicalb Vaginalb
Nonec 72 100.0 Negative Negative 72^ 72^
Single infection
HPV6 2 3.64c 1 50 2þ 2þ
HPV11 1 1.82 0 0 1þ 1þ
HPV16 35 63.64 29 82.86 29þ 29þ
HPV18 5 9.09 5 100 5þ 5þ
HPV33 4 7.27 3 75 4þ 4þ
Othersd 2 3.64 2 100 2þ 2þ
Mixed infection
HPV6/HPV16 1 1.82 1 100 1þ 1þ
HPV16/HPV18 3 5.45 3 100 3þ 3þ
HPV16/HPV33 2 3.64 2 100 2þ 2þ
aPercentage within group or subgroup.
bConfirmation of presence or absence of HPVDNA by PCR.
cHPV-negative women.
dHPVDNA-positive, but with genotype other than HPV6,11,16,18, or33.
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grade II (moderate) and CIN grade III (severe) cases were HPV-
positive (Table 2).
Detection of HPVDNA in cervical and vaginal scrapings
All endocervical and vaginal specimens were tested for the
presence of b-actin sequences, followed by amplification of
HPV consensus sequences using the MY09/MY11 primer pair.
Vaginal testing detected HPV DNA in all of the 55 HPV-
positive cervical scrapes and in none of the 72 HPV-negative
cervical scrapes (sensitivity¼ 1.0, specificity¼ 1.0) (Table 3). In
so far as all specimens screened were positive for b-actin, this
ruled out the possibility of loss of DNA integrity in the samples,
and/or non-specific inhibition of amplification.
Furthermore, HPV genotyping revealed that most of the
HPV-positive cases were HPV strain 16 (HPV16; 35/55), and a
number of double-positive specimens were obtained, exempli-
fied by three (5.45%) specimens positive for both HPV16
and HPV18 (Table 3). It was significant that the same HPV
genotype was obtained in both cervical and vaginal scrapes
of HPV-positive women. Thus all HPV-positive specimens and
all HPV-negative specimens of vaginal nature were truly posi-
tive and negative, respectively, when determined by cervical
scrapes (positive and negative predictive values¼ 1.0), and the
HPV type(s) detected in vaginal scrapes were identical to those
found in cervical scrapes (Table 3).
DISCUSSION
HPV DNA was detected in endocervical and vaginal scrapes of
women with abnormal cytology and also in those with normal
cytology, using the consensus primer set MY09/MY11 [13].
Excellent correlation was obtained in detecting HPV DNA
from both specimens. In addition, HPV genotype analysis
revealed that the same HPV genotype(s) were detected in
the endocervical specimen as were found in the vaginal scrapes,
thereby giving a 100% concordance rate for both sampling
procedures. The Ayre spatula used in this study as the collection
device (Figure 1) gave both consistent and reproducible
results [10], and was well tolerated, particularly by women
who were retested. This was reminiscent of earlier reports,
which documented the superiority of the Ayre spatula over
other collection devices, including cotton swabs and self-
administered tampons [10,12,14]. The use of the latter devices
was often associated with variable and generally lower rates of
HPV detection.
Although cytology screening (Papanicolaou smear) remains
widely adopted as the screening method of choice for detection
of CIN, interestingly in seven out of 55 HPV-positive women,
the cytology results were normal, thus indicating that cytology
screening cannot rule out HPV infection [5,15]. In addition, 15
of the HPV-negative women had signs of mild dysplasia (CIN
grade I), further suggesting that Papanicolaou smear results,
although strongly suggestive of infection [12], are not always
indicative of HPV infection. Other risk factors for HPV
infection seen here included smoking and sexual behavior, in
agreement with earlier reports [4,12].
Vaginal testing using an Ayre spatula as the collection device
resulted in a significant improvement in both sensitivity and
specificity over previous reports [10], where correlations of 80–
90% between vaginal and cervical sampling were obtained
[11,12]. Failure to produce complete concordance between
cervical and vaginal sampling was the result of sampling tech-
niques [12,14]. In our hands, the use of vaginal scrapes produced
sufficient quantities of cells [10,11], and the expression of the
constitutively expressed b-actin gene was always sought, thus
ruling out the possibility that absence of HPV PCR products
was related to specimen degradation, or to the presence of PCR
inhibitors, which collectively confirm the consistency and
efficacy of this sampling method [6,11].
HPV DNA was amplified by PCR using the MY09/MY11
primer pair, described as the primer pair of choice in detecting
HPV DNA [9,13]. All cervical and vaginal scrapes were col-
lected at the same time so as to rule out the possibility of
variation in viral load, and hence sensitivity, between the cervix
and vagina [8,11]. Although our study was limited by the
requirement for a gynecologist/technician for specimen collec-
tion [1,11], vaginal sampling was less invasive than endocervical
sampling, as no speculum was needed, and was fairly well
tolerated, since none of the participants experienced any dis-
comfort during the procedure. Vaginal testing is an easy yet
highly valid method for detecting HPV DNA. Correlation
between vaginal and cervical sampling methods was excellent,
in particular for the identification of specific HPV genotypes.
Accordingly, we recommend the use of vaginal sampling for
initial HPV screening, especially in women with cytomorpho-
logically normal smears, and/or where cervical testing may not
be feasible for many considerations, all of which necessitate the
need for appropriate sampling devices and techniques for the
detection of potential HPV infection. Owing to the excellent
correlation obtained with cervical sampling, vaginal sampling is
also useful in the long-term follow-up of HPV-infected women
for viral persistence, and hence in the monitoring of CIN
status [6].
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